<DOC>
	<DOCNO>NCT01341262</DOCNO>
	<brief_summary>The marked activity thalidomide ( thal ) dexamethasone ( dex ) relapse refractory multiple myeloma ( MM ) provide basis phase 2 clinical study aim investigate efficacy toxicity thal-dex incorporate melphalan-based double autologous stem cell transplantation ( ASCT ) patient le 65 year old newly diagnose symptomatic MM . Thal-dex give primary induction therapy continue throughout subsequent treatment phase day second autotransplantation . Primary study endpoint , evaluate intention treat basis , response rate different treatment phase ( induction , first second ASCT ) , best response whenever achieve , duration response ( DOR ) , time progression ( TTP ) , progression free survival ( PFS ) toxicity profile thal-dex . Secondary endpoint , evaluate intention treat basis , overall survival ( OS ) clinical outcome ( DOR , TTP , PFS OS ) accord prognostic factor , include cytogenetic abnormality image feature , detect 18F-FDG PET/CT .</brief_summary>
	<brief_title>THAL-DEX Incorporated Into Double PBSC Autotransplantation Untreated Multiple Myeloma ( MM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis symptomatic MM base standard criterion . No prior current systemic therapy MM , exception steroid . At least 18 year less 65 year age . Presence quantifiable M protein serum urine . Durie &amp; Salmon stage IIIII I disease progression . Adequate organ function ( heart , lung ) . No previous deep vein thrombosis and/or recur thrombophlebitis and/or pulmonary embolism , confirm doppler ultrasound compute tomography scan . Willing able comply protocol requirement . Exclusion criterion : Diagnosis smoulder asymptomatic MM , plasmacell leukemia , solitary plasmocytoma bone extramedullary plasmocytoma . Diagnosis nonsecretory MM . Prior current systemic therapy MM , exception steroid . More 65 year age . Female subject pregnant . Non adequate organ function ( heart , lung ) . Patient prior history thrombosis venous thromboembolism pulmonary embolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>autologous stem cell transplantation</keyword>
	<keyword>thalidomide</keyword>
	<keyword>induction therapy</keyword>
</DOC>